Uncovering a ‘suPAR’ culprit behind kidney injury in COVID-19

Michigan Medicine - University of Michigan

Newswise — Kidney injury is a dreaded complication in patients hospitalized for COVID-19, with more than a third of patients ending up in need of dialysis. Patients with COVID-19-related kidney injury are also at much higher risk of death.

“We don’t known exactly why patients with severe COVID-19 have a high rate of kidney injury,” says Salim Hayek, M.D., a cardiologist at the Michigan Medicine Frankel Cardiovascular Center and senior author of a new observational study.” It is, however, becoming clearer that a hyperactive immune system plays a major role in the morbidity of COVID-19, including kidney-related complications.”

In the multi-center study published in the Journal of the American Society of Nephrology, Hayek and an international team of experts report that levels of a protein in blood produced by immune cells and known to be involved in causing kidney disease are very high in patients hospitalized for COVID-19 and strongly predictive of kidney injury.

The research team tested soluble urokinase plasminogen activator receptor (suPAR) levels of 352 study participants when they were admitted to the hospital for COVID-19 infection.

A quarter of the participants developed acute kidney injury while hospitalized, and their median suPAR levels were more than 60% higher than those of the rest of the participants. The risk of needing dialysis was increased 20-fold in patients with the highest suPAR levels. Overall, median suPAR levels for these study participants hospitalized with severe COVID-19 were almost three times higher than levels of healthy people.

“SuPAR is an immune-derived circulating factor we’ve seen contribute to kidney injury in thousands of patients,” says Jochen Reiser, M.D., Ph.D., a professor of medicine at Rush University and expert in the biology of suPAR. “RNA viruses such as HIV and SARS-CoV-2 elicit a suPAR response of the innate immune system leading to a rise in blood suPAR levels. If there is a hyperinflammatory suPAR response, kidney cells may be damaged.”

Study author Subramaniam Pennathur, M.D., a professor of nephrology at Michigan Medicine, says identifying suPAR levels at hospital admission as a strong predictor for AKI during the hospitalization has important implications for future care.

“For example, obtaining suPAR levels may allow us to risk-stratify, i.e., identify high risk patients early, and institute appropriate preventive treatment, thereby reducing AKI risk and improving COVID-19 outcomes,” he says. “Second, therapies aimed at interrupting suPAR pathway may also be explored for preventative as well as a therapeutic option for COVID-19 AKI.”

Hayek, an expert on this protein is currently researching how best to reduce suPAR levels in those people at highest risk.

“We’re preparing to launch the first clinical trial targeting suPAR to prevent COVID-19 related kidney injury, and by doing so hope to alleviate the burden of kidney disease in both COVID-19 and non-COVID-19 patients with high suPAR levels,” he says.

Additional authors include Tariq Azam, Husam Shadid, Pennelope Blakeley, Patrick O'Hayer, Hanna Berlin, Michael Pan, Peiyao Zhao, Lili Zhao and Rodica Pop-Busui (Michigan Medicine); Izzet Altintas, Jens Tingleff, Marius Stauning, Ove Andersen and Jesper Eugen-Olisen (Copenhagen University Hospital); Maria-Evangelia Adami, Nicky Solomonidi, Maria Tsilika and Evangelos Giamarellos-Bourboulis (National and Kapodistrian University of Athens); Pinkus Tober-Lau and Frank Tacke (Charite Universitatsmedizin Berlin); Eleni Arnaoutoglou and Athanasios Chalkias (University of Thessaly) and Verena Keitel and Sven Loosen (University Hospital Düsseldorf).

Paper cited: “Soluble Urokinase Receptor in COVID-19 related Acute Kidney Injury.” Journal of the American Society of Nephrology.

SEE ORIGINAL STUDY




Filters close

Showing results

110 of 4155
access_time Embargo lifts in 2 days
Embargo will expire: 1-Dec-2020 9:15 AM EST Released to reporters: 30-Nov-2020 2:30 PM EST

A reporter's PressPass is required to access this story until the embargo expires on 1-Dec-2020 9:15 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise:Video Embedded covid-19-update-surge-preparedness-vaccine-distribution
VIDEO
Released: 30-Nov-2020 2:20 PM EST
COVID-19 Update: Surge Preparedness, Vaccine Distribution
Cedars-Sinai

With the novel coronavirus spreading across the U.S. at a record pace, Cedars-Sinai has been seeing an increase in COVID-19 patients at its hospitals and through its network of physicians. But the health system's leaders say Cedars-Sinai is prepared.

Released: 30-Nov-2020 1:20 PM EST
Rethink COVID-19 infection control to keep primary schools open this winter, governments urged
BMJ

An urgent rethink of infection control policies to keep COVID-19 infection at bay in schools is needed if primary schools are to be kept open this winter, and the knock-on effects on their families avoided, argue children's infectious disease specialists in a viewpoint, published online in the Archives of Disease in Childhood.

Newswise: Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Released: 30-Nov-2020 12:45 PM EST
Hackensack University Medical Center Urologists Continue to Provide State-of-the-Art Care During COVID-19
Hackensack Meridian Health

Don’t Delay Your Care – Our dnhanced pandemic safety precautions prioritize patient health and allow providers to deliver outstanding in-office, telehealth and surgical care

Released: 30-Nov-2020 12:10 PM EST
Struggles of care home staff during COVID-19 first wave revealed in Whatsapp messages
University of Leeds

Analysis of social media messages between care home staff on the coronavirus front line reveal their growing concerns over how to manage in the face of the virus.

Released: 30-Nov-2020 11:30 AM EST
More than one-third of children with COVID-19 show no symptoms: study
University of Alberta Faculty of Medicine & Dentistry

More than one-third of kids who have COVID-19 are asymptomatic, according to a University of Alberta study that suggests youngsters diagnosed with the disease may represent just a fraction of those infected.

Newswise: Promising lab results in quest to find naturally occurring anti-COVID therapies
24-Nov-2020 5:35 PM EST
Promising lab results in quest to find naturally occurring anti-COVID therapies
University of Alabama Huntsville

So far, 35 of 125 naturally occurring compounds identified computationally at The University of Alabama in Huntsville (UAH) to have potential against COVID-19 have shown efficacy in ongoing first-batch testing at the University of Tennessee Health Science Center’s Regional Biocontainment Laboratory (UTHSC RBL) that’s the next step in the process to becoming a drug.

Released: 30-Nov-2020 9:45 AM EST
Rutgers Leading Coronavirus Therapeutic Clinical Trial
Rutgers University-New Brunswick

Rutgers is leading a clinical trial assessing the efficacy of a three-drug combination in treating people infected with SARS-CoV-2 and asymptomatic or mildly symptomatic.

access_time Embargo lifts in 2 days
Embargo will expire: 1-Dec-2020 11:00 AM EST Released to reporters: 30-Nov-2020 8:40 AM EST

A reporter's PressPass is required to access this story until the embargo expires on 1-Dec-2020 11:00 AM EST The Newswise PressPass gives verified journalists access to embargoed stories. Please log in to complete a presspass application. If you have not yet registered, please Register. When you fill out the registration form, please identify yourself as a reporter in order to advance to the presspass application form.

Newswise: COVID-19 Peer Hub combats vaccine avoidance amid pandemic
Released: 27-Nov-2020 8:05 AM EST
COVID-19 Peer Hub combats vaccine avoidance amid pandemic
University of South Australia

UniSA researchers are evaluating a new vaccination education initiative – the COVID-19 Peer Hub – to help immunisation and public health professionals to tackle the emerging dangers of vaccine hesitancy amid the pandemic.


Showing results

110 of 4155

close
1.05637